Pfizer is making headlines with its $7.3 billion acquisition of Metsera, a weight loss drugmaker, as it aims to capture a share of the booming obesity drug market. This deal highlights the growing demand for innovative obesity treatments and Pfizer's strategic pivot following setbacks in its own drug pipeline.
GSK announces a groundbreaking $30 billion investment in the U.S. as President Trump visits the U.K. This commitment aims to enhance biopharma manufacturing and research, promising advancements in drug discovery and healthcare innovation.
Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.
The U.S. is facing unprecedented health care cost increases, with employers likely to pass on hefty paycheck deductions and out-of-pocket expenses to workers. A new survey reveals a perfect storm brewing for American health care.
In a bold move, the Trump administration is sending out 100 cease-and-desist letters to drug companies, aiming to eliminate misleading ads. This crackdown includes increased transparency about drug risks and closing loopholes that conceal vital safety information.
In a groundbreaking move, President Trump has signed a memorandum urging pharmaceutical companies to adhere to transparency laws in their advertising, especially on social media. This initiative aims to ensure accurate drug information and tackle misleading ads, marking a significant shift in health policy.
In a surprising policy shift, President Trump has directed a ban on TV drug advertising, a move that could reshape the pharmaceutical landscape and impact major networks. Discover the implications of this controversial decision!
In a bold move, President Trump calls for pharmaceutical companies to justify the success of their Covid drugs amid a leadership crisis at the CDC. As the FDA tightens vaccine eligibility, tensions rise over vaccine efficacy and public health transparency.
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
In a surprising turn, President Trump has retracted his plans for exorbitant tariffs on pharmaceuticals and semiconductors from the EU, capping them at 15%. This agreement, reached after intense negotiations, aims to stabilize trade relations and reduce costs for consumers and businesses.
